Sergio Amadori

Q: What Schools Are Affiliated With Sergio Amadori

Sergio Amadori is affiliated with the following schools: University of California, Berkeley, University of Eastern Piedmont, University of Bari, Stanford University, University of Florence, Leiden University

Sergio Amadori's AcademicInfluence.com Rankings

Sergio Amadori

Computer Science

#8209

World Rank

#8631

Historical Rank

Computational Linguistics

#1788

World Rank

#1806

Historical Rank

Machine Learning

#3294

World Rank

#3333

Historical Rank

Artificial Intelligence

#3598

World Rank

#3649

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Sergio Amadori's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Sergio Amadori Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Sergio Amadori's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017) (3878)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. (2010) (3011)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation (2017) (1382)
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. (2013) (1143)
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. (2005) (567)
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. (2001) (559)
Cancer‐related fatigue (2003) (439)
Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. (2004) (397)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. (2011) (392)
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. (2007) (376)
Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. (1990) (375)
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. (2003) (368)
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. (2008) (356)
Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. (1995) (353)
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. (2002) (344)
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). (2003) (343)
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. (2009) (331)
The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura (2004) (324)
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. (2010) (301)
Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. (2007) (299)
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. (2009) (294)
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. (2016) (270)
Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. (2000) (265)
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. (2017) (265)
Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management (2007) (262)
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. (2012) (258)
Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. (2008) (253)
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study (2013) (245)
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial (2005) (243)
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. (2010) (240)
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. (2006) (237)
Clinical significance of CD38 expression in chronic lymphocytic leukemia. (2001) (233)
Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. (2004) (220)
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. (2006) (195)
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. (2002) (193)
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. (2006) (179)
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. (2011) (178)
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. (2008) (161)
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. (2001) (153)
Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. (1991) (150)
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. (2005) (149)
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. (2014) (147)
Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults (2007) (137)
Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. (1993) (136)
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. (1996) (132)
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. (2009) (131)
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia (2005) (128)
Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. (2002) (128)
Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. (2006) (124)
Adolescent and adult acute lymphoblastic leukemia: prognostic features and outcome of therapy. A study of 293 patients. (1982) (124)
Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. (2010) (122)
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia (2006) (118)
Anaplastic large cell lymphoma (CD30+/Ki‐1+): results of a prospective clinico‐pathological study of 69 cases (1994) (116)
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies (2006) (107)
GIMEMA AML1310 TRIAL OF RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. (2019) (106)
Clinical significance of CD 38 expression in chronic lymphocytic leukemia (2001) (103)
Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. (2005) (101)
Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. (1996) (100)
Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. (2005) (100)
Mucositis in patients with hematologic malignancies: an overview. (2007) (100)
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes (2009) (98)
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. (2011) (97)
Long-Term Outcome of Otherwise Healthy Individuals with Incidentally Discovered Borderline Thrombocytopenia (2006) (96)
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia (1998) (96)
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. (2002) (94)
Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. (1999) (92)
Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy (1984) (91)
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B‐cell chronic lymphocytic leukemia (2008) (91)
Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. (1991) (91)
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. (2008) (87)
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). (2013) (86)
Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. (2019) (84)
Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. (2004) (83)
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. (2007) (80)
Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes. (1997) (80)
Expression of cellular oncogenes in primary cells from human acute leukemias. (1986) (78)
P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. (1993) (77)
Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. (2008) (74)
Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols (2003) (73)
Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes. (2014) (72)
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial (2010) (72)
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy (2016) (71)
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia (1999) (69)
The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial (2003) (67)
Temsirolimus, an mTOR inhibitor, in combination with lower‐dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML‐1107) (2012) (65)
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia (2012) (65)
Late multifocal gliomas in adolescents previously treated for acute lymphoblastic leukemia (1987) (65)
Mediastinal large B‐cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third‐generation regimens (1995) (62)
Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy (2005) (61)
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation (2003) (59)
Liposomal daunorubicin versus standard daunorubicin: long term follow‐up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia (2008) (57)
Infliximab chimaeric anti‐tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes (2002) (57)
Cytokinetically based induction chemotherapy and splenectomy for childhood acute nonlymphocytic leukemia. (1982) (55)
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. (2007) (54)
Randomized trial of two schedules of low‐dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML‐19) (2010) (53)
A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia (2015) (53)
Acute promyelocytic leukemia: clinical aspects and results of treatment in 62 patients. (1987) (52)
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP‐70‐negative chronic lymphocytic leukemia (2005) (52)
Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. (2008) (51)
Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP* experience (1994) (50)
Nerve growth factor: a survey of activity on immune and hematopoietic cells (1999) (48)
In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation. (1995) (48)
Intensive treatment of patients age 60 years and older with De novo acute myeloid leukemia: Analysis of prognostic factors (1996) (48)
High serum IL‐2 levels are predictive of prolonged survival in multiple myeloma (1990) (48)
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia (2016) (46)
Myelodysplastic syndromes: recent advances. (2001) (46)
Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent (2005) (46)
Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. (2000) (46)
Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? (2007) (46)
Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. (2000) (45)
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant. (2006) (45)
Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia (2013) (44)
An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations (2017) (44)
Acute leukaemia in patients treated for Hodgkin's disease (1984) (44)
Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia. (1990) (43)
Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. (2002) (43)
A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias. (1998) (43)
Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. (2013) (43)
Minimally differentiated acute myeloid leukaemia (AML‐MO): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases (1994) (43)
Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience. (1996) (43)
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. (2008) (42)
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy (2014) (42)
An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia. (2008) (42)
Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204. (1987) (42)
CD90/Thy‐1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias * (2004) (42)
Serum interleukin-2 (IL-2), soluble IL-2 receptors and tumor necrosis factor-alfa levels are significantly increased in acute myeloid leukemia patients. (1991) (41)
Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns. (2005) (41)
Identification of emerging FLT3 ITD‐positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin (2013) (41)
Recombinant human granulocyte‐macrophage colony‐stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes (1999) (41)
Combination chemotherapy for acute lymphocytic leukemia in adults: Results of a retrospective study in 82 patients (1980) (40)
A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature (2016) (40)
A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation (2006) (40)
Analysis of t(15;17) chromosomal breakpoint sequences in therapy‐related versus de novo acute promyelocytic leukemia: Association of DNA breaks with specific DNA motifs at PML and RARA loci (2010) (39)
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment (2014) (39)
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial (2019) (38)
P‐glycoprotein and BCL‐2 levels predict outcome in adult acute lymphoblastic leukaemia (2003) (38)
FISH analysis for CML monitoring ? (1996) (37)
CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study (2012) (36)
Molecular characterization of paediatric idiopathic hypereosinophilia (2010) (36)
Translocation of c‐myc into the immunoglobulin heavy‐chain locus in human acute B‐cell leukemia. A molecular analysis. (1986) (36)
Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. (2014) (36)
O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro. (2006) (36)
Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. (2011) (36)
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients. (2004) (35)
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. (1999) (34)
ALL R‐87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse (1997) (34)
ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG (2012) (34)
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial (2021) (34)
Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse (2009) (34)
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients (2015) (33)
Opioids in pain management of blood-related malignancies (2006) (33)
Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R‐87 protocol (1997) (33)
Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. (1993) (33)
Sequential combination of systemic high-dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma. (1984) (33)
Sequential combination chemotherapy of high-grade non-Hodgkin's lymphoma with 5-fluorouracil, methotrexate, cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine, and prednisone (F-MACHOP). (1987) (32)
Cryopreserved autologous bone marrow infusion following high dose chemotherapy in patients with acute myeloblastic leukemia in first relapse. (1985) (32)
Comparison between conventional banding analysis and FISH screening with an AML-specific set of probes in 260 patients. (2003) (32)
CD44 ligation on peripheral blood polymorphonuclear cells induces interleukin-6 production. (2001) (32)
Clinicopathologic Characterization of Diffuse-Large-B-Cell Lymphoma with an Associated Serum Monoclonal IgM Component (2014) (31)
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis (1996) (31)
P-glycoprotein expression in de novo acute myeloid leukemia. (1997) (31)
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. (2018) (31)
In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts (1997) (31)
Acute promyelocytic leukemia following ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and radiotherapy for Hodgkin's disease. (1983) (31)
Sequential combination of high dose ARA-C (HiDAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma. (1984) (30)
Relevance of CD 49 d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia (2007) (30)
Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. (2004) (29)
Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. (2006) (29)
Apoptosis and immaturity in acute myeloid leukemia (2005) (29)
Phase II trial of intermediate dose ARA-C (IDAC) with sequential mitoxantrone (MITOX) in acute myelogenous leukemia. (1989) (29)
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial (2014) (28)
The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia (2015) (28)
Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia. (1995) (28)
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation (2004) (28)
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results (2021) (28)
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. (2004) (27)
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods (1999) (27)
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. (2020) (27)
Discontinuing therapy in childhood acute lymphocytic leukemia a multicentric survey in Italy (1980) (27)
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes (2000) (26)
Chromosomal Aberration of the 11q23 Locus in Acute Leukemia and Frequency of MLL Gene Translocation Results in 378 Adult Patients (2004) (26)
High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma (2014) (26)
Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies. (2004) (26)
A Prospective Randomized Study Comparing Rituximab and Dexamethasone Vs Dexamethasone Alone in ITP: Results of Final Analysis and Long Term Follow up (2008) (25)
Lack of prognostic significance of the pretreatment labeling and mitotic indices of marrow blasts in acute nonlymphocytic leukemia (ANLL) (1978) (25)
Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC. (2005) (25)
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients (2013) (24)
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia. (2002) (24)
Treatment of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). (1982) (24)
Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. (2005) (24)
MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas. (1995) (23)
Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group (2010) (23)
Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group (2012) (23)
Identification of a potential “hotspot” DNA region in the RUNX1 gene targeted by mitoxantrone in therapy‐related acute myeloid leukemia with t(16;21) translocation (2009) (22)
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia (2017) (22)
Selective expression of fos proto-oncogene in human acute myelomonocytic and monocytic leukemias: a molecular marker of terminal differentiation. (1987) (22)
Infliximab chimeric antitumor necrosis factor-α monoclonal antibody as potential treatment for myelodysplastic syndromes (2005) (22)
Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial (2006) (22)
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) (2008) (22)
The F-MACHOP sequential combination chemotherapy regimen in advanced diffuse aggressive lymphomas: long-term results. (1991) (21)
Home care management of patients affected by hematologic malignancies: a review. (2006) (21)
Randomized multicentric Italian study on two treatment regimens for marrow relapse in childhood acute lymphoblastic leukemia. (1986) (21)
The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations (2017) (21)
Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment (1992) (21)
Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing. (2004) (20)
Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia. (2007) (20)
Collection of peripheral progenitor cells: a comparison between Amicus and Cobe-Spectra blood cell separators. (2004) (20)
Teicoplanin in the treatment of Gram‐positive bacteraemia in neutropenic patients (1990) (20)
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. (2016) (20)
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. (2003) (20)
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy (2013) (20)
Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia (2018) (20)
Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia (2019) (20)
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia (2008) (20)
High‐dose ARA‐C (HiDAC) plus asparaginase in elderly patients with acute non‐lymphocytic leukemia: A pilot multicentric study by the Italian cooperative group GIMEMA (1989) (19)
Novel Thrombopoietic Agents (2012) (19)
A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia. (1996) (18)
Phase III comparative trial (m-BACOD v m-BNCOD) in the treatment of stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology. (1990) (18)
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-α (IFN-α) therapy (1995) (18)
Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement. (1987) (18)
Treatment of diffuse aggressive non-Hodgkin's lymphomas with an intensive multi-drug regimen including high-dose cytosine arabinoside (F-MACHOP). (1985) (18)
Autologous stem‐cell transplantation for patients with acute myeloid leukemia aged over 60 yr (2002) (18)
Treatment of multiple myeloma: a randomized study of three different regimens. (1985) (18)
Bromodeoxyuridine treatment of normal adult erythroid colonies: an in vitro model for reactivation of human fetal globin genes. (1986) (18)
Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis (2010) (17)
Experience on the treatment of chronic myelocytic leukaemia (CML) in blastic crisis. (2009) (16)
Biological features of acute myeloid leukemia in the elderly. (1998) (16)
Blast cell kinetics and prognosis in acute nonlymphocytic leukemia. (1980) (16)
Long‐term survival in adolescent and adult acute lymphoblastic leukemia (2006) (16)
Efficacy of a combined treatment with ASTA-Z 7654 and VP16-213 in vitro in eradicating clonogenic tumor cells from human bone marrow. (1987) (16)
Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use. (2007) (16)
Treatment of primary refractory or relapsed acute lymphoblastic leukemia (ALL) in children. (1992) (16)
Placental/umbilical cord blood: experience of st. Eugenio Hospital collection center. (2005) (16)
Quantitative analysis of Fas and bcl-2 expression in hematopoietic precursors. (2001) (15)
High-dose chemotherapy in adult acute myeloid leukemia: rationale and results. (1996) (15)
Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocyte leukemia: a randomized collaborative study. (1978) (15)
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. (2006) (15)
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-M0) and its clinical implications. (1996) (15)
A randomized study of the efficacy of postconsolidation therapy in adult acute nonly mphocytic leukemia: a report of the Italian Cooperative Group GIMEMA (1992) (15)
The genotype nucleophosmin mutated and FLT3‐ITD negative is characterized by high bax/bcl‐2 ratio and favourable outcome in acute myeloid leukaemia (2010) (15)
All-trans retinoic acid (ATRA) administration during pregnancy in relapsed acute promyelocytic leukemia. (1995) (15)
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia. (2001) (14)
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications (2016) (14)
Sequential combination of methotrexate and L-asparaginase in the treatment of refractory acute leukemia. (1980) (14)
Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy. (2004) (14)
Clinical significance of c.7544‐7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia (2013) (14)
Combination chemotherapy for marrow relapse in children and adolescents with acute lymphocytic leukaemia. (2009) (14)
A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas. (1989) (14)
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study (2014) (14)
Short term treatment with Escheria coli recombinant human granulocyte‐macrophage–colony stimulating factor prior to chemotherapy for Hodgkin disease (2000) (13)
Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia. (2012) (13)
A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype. (1997) (13)
Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study (2017) (13)
Academic promotion in Italy (1992) (13)
The role of angiogenesis in hematologic malignancies. (2002) (13)
[Antiphospholipid antibodies: their prevalence, clinical significance and correlation with cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma]. (1995) (13)
Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia (2010) (13)
Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia. (1997) (12)
Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients (2020) (12)
AML-M0: a review of laboratory features and proposal of new diagnostic criteria. (1999) (12)
Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia (2018) (12)
Combination chemotherapy for the treatment of diffuse aggressive lymphomas: F-MACHOP update. (1987) (12)
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013) (2015) (12)
Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia – Updated Results of the Italian-German APL0406 Trial on the Extended Final Series (2014) (12)
High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT (2015) (12)
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase III study (2020) (12)
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage (2015) (12)
Diagnosis and classification of the acute leukemias: recent advances and controversial issues. (1996) (12)
Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype (2018) (11)
Prognostic value of cytogenetics and multidrug resistance (MDR1) in elderly patients with acute myeloid leukemia. (1998) (11)
Mediastinal extramedullary hematopoiesis as first manifestation of hereditary spherocytosis (1992) (11)
Randomized clinical trial of immunotherapy and androgenotherapy for remission maintenance in acute non-lymphocytic leukemia. (1981) (11)
Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23+/mll+ translocation in leukaemia (2003) (11)
Minimal residual disease as biomarker for optimal biologic dosing of ARA‐C in patients with acute myeloid leukemia (2015) (11)
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies (2014) (11)
Evaluation of a polychemotherapeutic regimen including Idarubicin (4-demethoxydaunorubicin) in relapsed acute lymphocytic leukemia. (1986) (11)
Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study. (2016) (10)
Red blood cell depletion of cord blood using hydroxyethylstarch double sedimentation: analysis of 40 cases. (1998) (10)
Multidimensional Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia (2003) (10)
Long‐term survival in childhood acute lymphocytic leukemia in Italy (1981) (10)
Femoral Catheters: Safety and Efficacy in Peripheral Blood Stem Cell Collection (1999) (10)
Daunorubicin, cytosine arabinoside and 6-thioguanine (DAT) combination chemotherapy for the treatment of acute non-lymphocytic leukemia. (1979) (9)
Vindesine in the treatment of refractory hematologic malignancies: a phase II study. (1982) (9)
Allogeneic or autologous bone marrow transplantation for intensification of salvage therapy in patients with high-risk advanced acute lymphoblastic leukemia. The AIEOP/GIMEMA Groups. (1991) (9)
Phase 1 / 2 study to assess the safety , efficacy , and pharmacokinetics of barasertib ( AZD 1152 ) in patients with advanced acute myeloid leukemia (2011) (9)
Monitoring of minimal residual disease in acute myeloid leukemia (2009) (9)
Recurrence of a t(8;21)-Positive Acute Myeloid Leukemia in the Form of a Granulocytic Sarcoma Involving Cranial Bones: A Diagnostic and Therapeutic Challenge (2013) (9)
Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825. (2006) (8)
Genomic profiling and predicting treatment response in acute myeloid leukemia. (2019) (8)
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients (2011) (8)
Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia (2006) (8)
Biological monitoring of Italian soldiers deployed in Iraq. Results of the SIGNUM project. (2016) (8)
Role of human leukocyte interferon-alpha in the treatment of patients with polycythemia vera. (1998) (8)
Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach (2018) (8)
Extensive toxic epidermal necrolysis following brentuximab vedotin administration (2015) (8)
MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia. (1995) (8)
Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia (2009) (8)
Allogeneic vs autologous stem cell transplantation according to cytogenetic features in AML patients (pts) <= 45 yrs old in first CR: Results of the EORTC-GIMEMA AML-10 trial (2001) (8)
1040TiPQuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML) (2017) (7)
Biological pattern of AML-M0 versus AML-M1: response. (1997) (7)
All‐trans retinoic acid (ATRA) in non‐promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low‐dose Ara‐C in three elderly patients with NPM1‐mutated AML unfit for intensive chemotherapy and review of the literature (2016) (7)
Therapeutic strategies for postremission treatment in childhood acute myeloid leukemia (AML). The AIEOP experience 1987-1991. (1992) (7)
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors. (2002) (7)
Monoclonal antibodies and immunoconjugates in acute myeloid leukemia. (2006) (7)
DHAP treatment: results of 18 patients with refractory or recurrent non Hodgkin's lymphoma. (1990) (7)
Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party (2008) (6)
Therapy of childhood acute myelogenous leukemia: an update of the AIEOP/LAM 8204 study. Italian Pediatric Hematology-Oncology Association. (1990) (6)
Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials (2020) (6)
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes. (2013) (6)
Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia (2008) (6)
Treatment of Acute Myeloid Leukemia with 20–30% Bone Marrow Blasts (2013) (6)
Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-alpha (IFN-alpha) therapy. (1995) (6)
High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients (2009) (6)
PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells (2007) (6)
Longitudinal detection of DNMT3AR882H transcripts in patients with acute myeloid leukemia (2018) (6)
A Leukemia-Associated CD 34 / CD 123 / CD 25 / CD 99 þ Immunophenotype Identi fi es FLT 3-Mutated Clones in Acute Myeloid Leukemia (2015) (6)
Diagnosis of acute foetal distress does not preclude banking of umbilical cord blood units (2006) (6)
Apoptosis Resistance and NOTCH1 Mutations Impair Clinical Outcome in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Ibrutinib (2017) (6)
Pyrrolo[1,2‐b][1,2,5]benzothiadiazepines (PBTDs) exert their anti‐proliferative activity by interfering with Akt–mTOR signaling and bax:bcl‐2 ratio modulation in cells from chronic myeloid leukemic patients (2010) (6)
Prognostic Impact of Insertion Site in Acute Myeloid Leukemia (AML) with FLT3 Internal Tandem Duplication: Results from the Ratify Study (Alliance 10603) (2018) (6)
Long Term Follow up Analysis Following Front Line Therapy with Dexamethasone or Dexamethasone Plus Rituximab in Adults with Primary Immune Thrombocytopenia. (2009) (5)
Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial (2016) (5)
Rituximab Maintenance Following Chemoimmunotherapy Improves Outcome in B-Cell Chronic Lymphocytic Leukemia. (2009) (5)
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood. (1998) (5)
AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3-Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML). (2022) (5)
Efficacy and safety of human leucocyte interferon‐α treatment in patients younger than 60 years of age with polycythaemia vera (1997) (5)
Consolidation and Maintenance Immunotherapy with Rituximab Improve Progression Free Survival within ZAP-70 Positive Chronic Lymphocytic Leukemia (CLL). (2006) (5)
Contribution of immunophenotypic and genotypic analyses to the diagnosis of acute leukemia (1995) (5)
Addition of Rituximab to Fludarabine Improves Progression Free Survival in Untreated ZAP-70 Negative Chronic Lymphocytic Leukemia (CLL). (2004) (5)
Bisantrene in relapsed and refractory acute myelogenous leukemia. (1993) (5)
The optimal dosing of gemtuzumab ozagamicin: where to go from here? (2016) (5)
Unrelated cord blood transplantation for children with high risk myelodysplastic syndromes. (2004) (5)
Evaluation of the prognostic relevance of l‐selectin and ICAM1 expression in myelodysplastic syndromes (2007) (5)
Up-Front Window Trial of Gemtuzumab Ozogamicin (GO) in Previously Untreated Elderly Patients with AML: An EORTC Leukemia Group Study. (2004) (5)
Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients (2013) (4)
Erratum: The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia (2016) (4)
Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON leukemia group trials (2013) (4)
MEN1112/OBT357, an Anti Bst1/CD157 Humanized Antibody Inducing Acute Myelogenous Leukemia (AML) Blast Depletion in an Autologous Ex Vivo Assay: A Potential New Targeted Therapy for AML (2015) (4)
Clinical Significance of Apoptosis Is Independent from Proliferation in Acute Myeloid Leukemia (AML). (2004) (4)
Stem cell transplantation in ALL : a donor versus no donor comparison in the EORTC ALL-4 study (2007) (4)
Glucose-6-phosphate dehydrogenase Velletri. (1977) (4)
Gemtuzumab ozogamicin in combination with intensive chemotherapy for relapsed/refractory acute myeloid leukemia (2009) (4)
Rituximab Consolidation and Maintenance Immunotherapy Improve Outcome in B-Cell Chronic Lymphocytic Leukemia. (2007) (4)
A novel t(11;12)(q23-24;q24) in a case of minimally-differentiated acute myeloid leukemia (AML-M0). (2000) (4)
Sequential administration of gemtuzubab ozogamicin (GO) and intensive chemotherapy for remission induction in previously untreated patients with AML over the age of 60: Interim results of the EORTC leukemia group AML-15A phase II trial (2001) (4)
Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia (2006) (4)
Effects of cell banking manipulations on ex vivo amplification of umbilical cord blood. (2000) (4)
A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy (2015) (4)
Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia. (2006) (4)
[Anemia induced by solid tumor chemotherapy]. (2002) (4)
recommendations from an international expert panel, on behalf of the Diagnosis and management of acute myeloid leukemia in adults: (2010) (4)
[Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study]. (2002) (4)
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient. (2008) (4)
High CD69 Protein Expression Predicts a Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia (B-CLL). (2007) (4)
Liposomal daunorubicin plus cytosine arabinoside for elderly patients with acute myeloid leukemia: The gimema experience (2000) (4)
Erratum: Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia (Leukemia (2005) vol. 19 (1479-1482) 10.1038/sj.leu.2403846) (2007) (4)
Advances in the treatment of elderly and frail patients with acute myeloid leukemia (2014) (4)
Flow cytometric measurement (H-1 Technicon) of microcytic and hyperchromic red cell populations in pediatric patients affected by hereditary spherocytosis (HS). (1989) (4)
Role of Human Leukocyte Interferon-a in the Treatment of Patients With Polycythemia Vera (1998) (4)
Rituximab in the treatment of autoimmune haematological disorders (2008) (3)
Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials (2018) (3)
E‐rosette positive acute lymphoblastic leukaemia in adolescents and adults (1983) (3)
Quantum-First Trial: FLT3-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival (2022) (3)
Quantitative analysis of P-glycoprotein, bcl-2 and transferrin receptor allows the stratification of acute myeloid leukemia patients within different prognostic risk classes. (1997) (3)
2-Methyl-9-hydroxyellipticinium acetate (ellipticinium) in the treatment of lymphomas. Preliminary results of a phase II study. (1984) (3)
ZAP-70 Protein Retains Its Prognostic Significance within Interphase Cytogenetic Groups in B-Cell Chronic Lymphocytic Leukemia (B-CLL). (2004) (3)
Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation. (2004) (3)
Allogeneic vs autologous stem cell transplantation according to cytogenetic and FAB features in AML patients (pts) <=45 yrs old in CRI: Results of the EORTC-GIMEMA AML-10 trial (2002) (3)
Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL): An Update of the GIMEMA Experience. (2009) (3)
Therapy of Adult Acute Lymphoblastic Leukemia. Preliminary Results of the GIMEMA ALL/0288 Study (1994) (3)
Splenectomy in early chronic myeloid leukaemia: preliminary report on 37 cases. (1974) (3)
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative (2019) (3)
Third-line chemotherapy with CAVP (CCNU, melphalan, etoposide and prednisone) in refractory Hodgkin's disease. (1989) (3)
Valproic Acid Plus Retinoic Acid Induce Myeloid Differentiation in Chemotherapy-Resistant Acute Myeloid Leukemia Patients. (2004) (3)
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial (2022) (3)
Autologous bone marrow transplantation in patients with AML in second complete remission (CR). (1989) (3)
Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells (2011) (3)
Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy (2018) (3)
Variable Outcome of Allogeneic Stem Cell Transplant According to the Different Levels of Pre-Transplant Minimal Residual Disease, in Adult Patients with Acute Myeloid Leukemia (2015) (3)
Autologous Peripheral Blood Stem-Cell (PBSC) Collection Is Not Impaired by Bortezomib-Thalidomide-Dexamethasone (VTD) Induction Therapy in Newly Diagnosed Multiple Myeloma (MM) (2011) (3)
Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107) (2010) (3)
Myelodysplastic syndromes in childhood: description of seven cases (1994) (3)
AML-M0: a biological and clinical profile (1998) (3)
HIGH SERUM INTERLEUKIN‐2 LEVELS IN ACUTE MYELOID LEUKAEMIA (AML) ARE ASSOCIATED WITH FAB M4 AND M5 SUBTYPES (1989) (3)
Simultaneous occurrence of BCR/ABL1 and RUNX1/RUNX1T1 in a case of therapy-related acute myeloid leukemia. (2009) (2)
A new system for quality control in hematopoietic progenitor cell units before reinfusion in autologous transplant (2014) (2)
Preliminary results of the combination methotrexate-asparaginase in patients with acute non lymphoid leukemia. (1978) (2)
Blood coagulation abnormalities in chronic myeloid leukaemia. (1972) (2)
Impact on Mental Health, Disease Management and Socioeconomic Modifications in Hematological Patients during COVID-19 Pandemia in Italy (2020) (2)
Allogeneic vs autologous BMT vs intensive chemotherapy in childhood AnLL during first complete remission: AIEOP experience. AIEOP Cooperative Group. (1991) (2)
Treatment of acute nonlymphocytic leukemia (ANLL) in elderly patients. Results of a multicentric study. (1979) (2)
Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia (2009) (2)
Results of the Italian AIEOP/LAM 8204 study for the treatment of childhood AML: an update. (1989) (2)
Cytokinetic studies in chronic lymphocytic leukemia. Relationship to other variables at diagnosis and survival. (1980) (2)
Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3-Internal Tandem Duplication: Results from the Quantum-First Trial (2022) (2)
The Amount of Spontaneous Apoptosis Is An Independent Strong Disease Progression Indicator in B-Cell Chronic Lymphocytic Leukemia (B-CLL) (2009) (2)
Red blood cell depletion and cryopreservation of umbilical cord blood (UCB) (1997) (2)
Phase II–III Study of Gemtuzumab Ozogamicin Monotherapy versus Best Supportive Care in Older Patients with Newly Diagnosed AML Unfit for Intensive Chemotherapy: First Results of the EORTC-GIMEMA AML-19 Trial (2008) (2)
Therapy of Acute Nonlymphocytic Leukemia in Children: A Review of 73 Patients 1 (1981) (2)
Serum Interleukin‐11 in Plasma‐Cell Dyscrasias (1996) (2)
Diffuse-Large-B-Cell Lymphoma Patients with Secretory IgM Monoclonal Component Are A Very Poor Prognostic Subset. (2012) (2)
Subcutaneous Administration of Interleukin-2 Triggers Fc&ggr; Receptor I Expression on Human Peripheral Blood Neutrophils in Solid and Hematologic Malignancies (2001) (2)
Risk-Adapted, MRD-Refined Therapeutic Approach for the Treatment of Acute Myeloid Leukemia: From a Single Center Experience to the Cooperative Gimema Protocol AML1310 (2012) (2)
New drugs in acute myeloid leukemia (2014) (2)
New agents for the treatment of acute myeloid leukemia: gemtuzumab ozogamicin (2009) (2)
F-MACHOP in advanced aggressive lymphoma. (1992) (2)
Comparison of rHuEpo plus rHuG-CSF and supportive care: apples to oranges. (2004) (2)
Treating older patients with AML. (2012) (2)
High serum interleukin-2 levels in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. (1989) (2)
Clinical Significance of CD69 Expression In Chronic Lymphocytic Leukemia (2010) (2)
Genomic Aberrations Dramatically Improve The Strong Prognostic Impact Of IGHV Mutational Status In Chronic Lymphocytic Leukemia (CLL) (2013) (2)
New trends in the treatment of adult acute myeloid leukaemia (1997) (2)
Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation (2021) (1)
detection in acute myeloid leukemia Prognostic and therapeutic implications of minimal residual disease (2012) (1)
Acute Erythroid Leukemia: A Distinctive Subtype of AML? Outcome and Prognostic Factors in Comparison with Non-M6 AML. The Gimema Experience. (2009) (1)
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation (2007) (1)
Prognostic factors in adult acute lymphoblastic leukemia (ALL). (1989) (1)
Allogeneic SCT planned in CR-1 after intensive chemotherapy in patients with bad prognosis MDS results in better outcome in the intermediate/high-risk cytogenetic group: a study by the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups (2006) (1)
Expression of c‐fos in Human Normal and Neoplastic Monocyte‐Macrophage Differentiation a (1987) (1)
The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL) (2018) (1)
PS1003 HARMONY ALLIANCE: EUROPEAN PUBLIC-PRIVATE DATA COLLECTION LEADS THE WAY - FIRST RESULTS OF THE “PROOF-OF-PRINCIPLE” STUDY IN ACUTE MYELOID LEUKEMIA (2019) (1)
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood (1998) (1)
Autologous stem cell transplantations in elderly AML patients (1996) (1)
The F-MACHOP regimen in advanced diffuse aggressive lymphomas: summary of ten years' experience at a single institution. (1991) (1)
Peptide-Vaccine Treatment Associated with TKI Therapy in Patients with CML Is Able to Induce Immunologic, Cytogenetic and Molecular Responses: a Single Center Experience with Long-Term Follow up. (2009) (1)
High CD79b Expression Predicts a Poor Outcome in B-Cell Chronic Lymphocytic Leukemia (B-CLL). (2008) (1)
P-18 A new prognostic score foroutcome of patients with high-risk myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (SAML) after intensive antileukemic treatment (2005) (1)
Monitoring of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia Using Peripheral Blood (PB) as an Alternative Source to Bone Marrow (BM). (2005) (1)
Targeting and Depletion of Acute Myeloid Leukemia Blasts By MEN1112, a Novel Humanized Defucosylated Monoclonal Antibodies with Specificity for Bst1/CD157 Antigen (2014) (1)
Bendamustine Improves Clinical Outcome in Chronic Lymphocytic Leukemia (CLL) According to Different Clinical and Biological Prognostic Factors (2014) (1)
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial (2023) (1)
O07 Dexamethasone versus methyl-prednisolone for adult acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma (NHL) in patients ≤60 yrs old: final results of the EORTC ALL-4 Phase III Trial (2007) (1)
OP08 High dose (HD-AraC) vs standard dose cytosine arabinoside (SD-AraC) during induction in acute myelogenous leukemia (AML): Impact on stem cell mobilization after consolidation and on autologous transplantation (AML-12 trial) (2007) (1)
Growth kinetics of minimal tumour masses: implications for rational chemotherapy. (1981) (1)
Nucleophosmin Gene Mutations Exhibit High Spontaneous Apoptosis and Favorable Prognosis in Acute Myeloid Leukemia. (2007) (1)
Incidence and Clinical Impact of TET2 Mutations in Acute Myeloid Leukemia Patients Treated within the EORTC/GIMEMA AML-12/06991 AML Trial. (2009) (1)
YNK01, an Oral Cytosine Arabinoside Derivative in Acute Myeloid Leukemia and Chronic Myeloid Leukemia (1997) (1)
Prognostic Impact of Genetic Characterization in the GIMEMA LAM99P Study for Newly Diagnosed Adult AML. Relevance of Combined Analysis of Conventional Karyotyping, FLT3 and NPM Mutational Status. (2005) (1)
Clinical Significance of NOTCH1 mutations in Chronic Lymphocytic Leukemia. (2012) (1)
SEQUENTIAL THERAPY WITH VAD, BORTEZOMIB AND CYCLOPHOSPHAMIDE AS INDUCTION THERAPY FOR MULTIPLE MYELOMA: A SEQUENTIAL PHARMACOLOGIC COMBINATION TO ACHIEVE COMPLETE REMISSIONS BEFORE STEM CELL TRANSPLANTATION (2008) (1)
Apoptosis and Proliferation Synergistically Determine Overall Survival in Chronic Lymphocytic Leukemia (CLL) (2015) (1)
Treatment of acute nonlymphoid leukaemia with five different schedules including cytosine arabinoside and 6-thioguanine. (1977) (1)
High Dose (HD-AraC) vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction in Acute Myelogenous Leukemia (AML): Impact on Stem Cell Mobilization after Consolidation and on Autologous Transplantation (Second Report of the EORTC-Leukemia Group (LG) - GIMEMA AML-12 Trial. (2006) (1)
Clofarabine in combination with a standard remission induction regimen in patients 18-60 years old previously untreated intermediate an bad risk actue myelogenous leukemia (AML) or high risk myelodysplasia (MDS): combined phase I/II results of the EORTC/Gimema AML-14A trial (2014) (1)
Immunotherapeutic Maintenance Strategy Prolongs Response Duration and Overall Survival Preventing Relapse in Chronic Lymphocytic Leukemia (CLL) (2011) (1)
Long-term survival in adult acute leukemia. A multicenter study of 56 patients. (1982) (1)
Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603) (2018) (1)
Dexamethasone Versus Methyl-Prednisolone in Induction Therapy for Adult Acute Lymphoblastic (ALL) and Non-Hodgkin Lymphoma (NHL) Patients ≤ 60 Yrs Old: Final Results of the Eortc All-4 Phase III Trial. (2005) (1)
Risk allocation of adult patients with non-M3 acute myeloid leukemia (2013) (1)
Evolving Criteria of Donor Selection for Allogeneic Transplant in Acute Myeloid Leukemia (2015) (1)
Erratum: Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant (Journal of Medicinal Chemistry (2006) 49, (5840)) (2006) (1)
Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL) (2018) (1)
New agents for the treatment of acute myeloid leukemia: midostaurin (2009) (1)
Iron Chelation Therapy with Deferasirox In Transfusion Dependent Myelodysplastic Syndrome Patients. Preliminary Report From the Prospective MDS0306 GIMEMA Trial (2010) (1)
ERRATUM: Myelodysplastic syndromes: Recent advances (Haematologica (2001) 86 (1124-57)) (2001) (1)
Fludarabine, Cytarabine and Gentuzumab Ozogamicin (FLA-GO) as Salvage Therapy and Bridge to Transplant in Adult Relapsed Acute Myeloid Leukemia (AML) Patients (2017) (1)
Clinical and biological aspects of acute monocytic leukemia (a retrospective study of 29 patients). (1982) (1)
Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology? (2013) (1)
Red blood cell depletion and cryopreservation of umbilical cord blood (UBC) (1997) (1)
Phase II Study of Bortezomib as a Single Agent In Patients with Relapsed/Refractory or De Novo Acute Myeloid Leukemia Unfit for Intensive Therapy (2010) (1)
Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk mds and secondary aml treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups (2001) (1)
PF260 PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY (2019) (0)
The alpha 2 (r) interferon in the treatment of hairy cell leukemia: progressive report of 25 cases. (1987) (0)
disease prognosticator in chronic lymphocytic leukemia Relevance of CD 49 d protein expression as overall survival and progressive (2007) (0)
The Kinetic of Reduction of Minimal Residual Disease Impacts on duration of Response snd Survival of Patients with Acute Myeloid Leukemia. (2004) (0)
Acute foetal distress and umbilical cord blood banking (2007) (0)
The prognostic impact of cytogenetic features and clonality of patients with poor risk MDS and secondary AML (sAML) after treatment with intensive chemotherapy and stem cell transplantation for the treatment: a joint study oft he EORTCS, EBMT, SAK, HOVO (2001) (0)
Age-Stratified Analysis Of The Prognostic Role Of Minimal Residual Disease Detection By Flow Cytometry, In Adult Patients With Acute Myeloid Leukemia (2013) (0)
Allogeneic Transplant in Acute Myeloid Leukemia (AML) According to the Policy of the Rome Transplant Network (RTN): An Intention-to-Treat Analysis (2015) (0)
Correlation of high CD49d expression with disease progression and need for therapy in chronic lymphocytic leukemia (CLL) patients (2007) (0)
Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia (2021) (0)
Mitoxantrone, Etoposide, and Intermediate-Dose Cytosine Arabinoside (MEC): An Effective Regimen for Refractory Acute Myeloid Leukemia (1992) (0)
MRD-Directed Post-Remissional Therapy Dramatically Improves Outcome of Adult Patients with High Risk AML by Implementing Allogeneic Transplant Option (2010) (0)
OP11 AMLinolderpatients:theEORTC/GIMEMA experience (2007) (0)
Automated Haematology Analysers in Acute and Chronic Leukaemias (1998) (0)
Fulminant B Hepatitis in a Hepatitis B Surface Antigen-Negative Patient after Rituximab Therapy for B-CLL. (2005) (0)
thrombocytopenia than dexamethasone monotherapy in adults with primary immune Dexamethasone plus rituximab yields higher sustained response rates (2011) (0)
In Acute Myeloid Leukemia, the Use in Induction of Standard Dose Arac Is Associated with a Better Quality of Response as Compared to An Induction Regimen Containing High Dose Arac. (2009) (0)
The Amount of Mitochondrial Apoptosis Exerts Prognostic Impact on Normal Karyotype Acute Myeloid Leukemia. (2008) (0)
Comparative analysis of the expression of differentiation and adhesion molecules on progenitor cells from bone marrow , umbilical cord blood and leukapheresis product (1996) (0)
Value of allogeneic stem cell transplantation (SCT) versus autologous SCT and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial (2010) (0)
Author reply (0)
Drug-induced kinetic perturbations of the marrow blasts in acute leukemia. Effects of the daunorubicin, cytosine arabinoside and 6-thioguanine combination. (1979) (0)
Value of allogeneic stem cell transplantation (SCT) versus autologous SCT and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial (2010) (0)
Mitoxantrone as single agent in acute refractory leukemia (1986) (0)
49 The influence of cytogenetic abnormalities on treatment outcome after intensive antileukemic therapy for patients with high risk MDS (1997) (0)
State-of-the-Art Review The Role of Angiogenesis in Hematologic Malignancies (2002) (0)
The Phosphatidylinositol-3-Kinase Inhibitor BKM120 Impairs Proliferation and Induces Pro-Apoptotic Effects In Acute Myeloid Leukemia (2013) (0)
Methotrexate followed by L-asparaginase for the treatment of acute non lymphoid leukemia. (1985) (0)
Long Term Follow up on Patients with Ph-Abnormal Clones Emerged during Imatinib Therapy. (2006) (0)
High expression levels of vla-4 (CD49d) on mobilised peripheral blood stem cells are associated with rapid engraftment in multiple myeloma patients receiving autologous transplant (2012) (0)
Intensive chemotherpay versus autologous stem cell transplantation (ASCT) for the treatment of patients with poor risk MDS and secondary AML (sAML) (2000) (0)
50th Anniversary of Acta Haematologica (1998) (0)
Preclinical evaluation of the PI3K inhibitor, BKM120, in acute myeloid leukemia (2014) (0)
[Behavior of certain erythrocyte enzymes and metabolites in the course of Vaquez' syndrome and in patients with secondary cardiogenic and pulmonary polycythemia]. (1972) (0)
AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial. (2021) (0)
Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013) (2015) (0)
Questions on Hematopoietlc Stem Cells and AML (2003) (0)
Spontaneous Apoptosis and Proliferation Predict Disease Progression within ZAP-70 Negative B-Cell Chronic Lymphocytic Leukemia (B-CLL). (2005) (0)
[Acute hemolytic anemia in a patient with ictero-hemoglobinuric favism following the ingestion of an antitussive drug]. (1972) (0)
A New Prognostic Disease Specific Model To Predict Survival after Intensive Antileukemic Treatment for Young Patients with Poor-Risk MDS and AML: Results of the CRIANT and AML-10 Studies Conducted by the EORTC/GIMEMA/SAKK/HOVON/EBMT Groups. (2004) (0)
The impact of a 7-day prednisone (PDN) pretreatment in adult (less than 60y) acute lymphoblastic leukemia (ALL) therapy: results of LAL2000 vs LAL0496. (2011) (0)
Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by ﬂow cytometry improves risk stratiﬁcation in adult acute myeloid leukemia (2010) (0)
Idarubicn and high dose ARA-C in refractory ALL patients (1987) (0)
Pre-clinical activity of the PI3K inhibitor BKM120 on acute myeloid leukemia (2014) (0)
Autografting in high risk MDS and sAML (2000) (0)
The impact of anthracyclines on feasibility of subsequent autologous or allogeneic transplantation and induced marrow toxicity: interim results of the EORTC - GIMEMA AML-10 trial (2001) (0)
A NEW HUMAN ERYTHROLEUKEMIC LINE: INITIAL CHARACTERIZATION AND HEMIN-INDUCED ERYTHROID DIFFERENTIATION (1984) (0)
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia (2007) (0)
lymphocytic leukemia Clinical significance of ZAP-70 protein expression in B-cell chronic (2013) (0)
Authors' Response to Zimmer et al (2006) (0)
Clinical and pathological restaging in aggressive non-Hodgkin's lymphomas. (1991) (0)
[Preliminary studies on the effectiveness of the association cytosine-arabinoside, thioguanine, hydroxyureas in the treatment of blastic crisis in chronic myeloid leukemia]. (1972) (0)
Detection of Minimal Residual Disease by Flow-Cytometry Otimizes Risk Stratification When Combined with Cytogenetics in AML. (2007) (0)
Clinicopathological features of 19 DLBCL with a serum monoclonal IgM protein. (2014) (0)
Normal Fish Cytogenetics and 13q Deletions Unveil Marked Biological and Clinical Heterogeneity In Chronic Lymphocytic Leukemia (2010) (0)
A Leukemia-Associated CD 34 / CD 123 / CD 25 / CD 99-positive Immunophenotype Identifies FLT 3-mutated Clones in Acute Myeloid Leukemia (2015) (0)
Late intensification therapy for childhood acute lymphocytic leukemia. (1982) (0)
Induction of Apoptosis by Pyrrolobenzothiadiazepines (PBTDs) in cell lines and in 12 chronic myeloid leukaemia patients and imatinib-resistant (2004) (0)
Multidrug Resistance Proteins Overexpression Worsen the Favorable Clinical Impact of an Elevated Spontaneous Apoptosis in Acute Myeloid Leukemia (AML). (2006) (0)
208 Iron chelation therapy with deferasirox in transfusion dependent myelodysplastic syndrome patients. Preliminary report from the prospective MDS0306 GIMEMA trial (2011) (0)
Decisional Algorithm to Incorporate Hematopoietic Stem Cell Transplantation in the Management of Adult Patients with Acute Myeloid Leukaemia. (2008) (0)
Intensive Chemotherapy Followed by Stem Cell Transplantation for the Treatment of Myelodysplastic Syndromes (2001) (0)
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells (2000) (0)
EORTC Leukemia Group achievements (2012) (0)
Pattern of Central Nervous System (CNS) Involvement in Adult Acute Myeloid Leukemia (AML) and Its Impact on Outcome (2016) (0)
Assessment of Two Doses of Infliximab in Patients with Low/Intermediate Risk IPSS Myelodysplastic Syndrome (MDS): An EORTC Leukemia Group (LG) Randomized Phase II Trial (06023). (2007) (0)
IN MYELOMA PATIENTS TREATED WITH MELPHALAN 100mg/m2 OR MELPHALAN 200mg/m2 OUTCOME IS NOT SIGNIFICANTLY DIFFERENT (2000) (0)
Treatment of Low-Blast Count AML using Hypomethylating Agents (2017) (0)
progressive disease prognosticator in chronic lymphocytic leukemia Relevance of CD49d protein expression as overall survival and (2013) (0)
ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms. (2023) (0)
Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database (2021) (0)
The Kinetics of Reduction of Minimal Residual Disease Impacts on Duration of Survival and Response of Adult Patients with Acute Myeloid Leukemia. (2005) (0)
Combination chemotherapy of unfavourable prognosis non-Hodgkin's lymphomas (NHL). A retrospective study of 53 cases. (1981) (0)
Clinicopathologic Characterization of Igm-Secreting Diffuse-Large-B-Cell Lymphoma (2014) (0)
[Total serum copper in histiocyte sarcomatosis with a systemic tendency]. (1972) (0)
The pan-class I PI3 kinase inhibitor, NVP-BKM120, demonstrates anti-leukemic activity in acute myeloid leukemia (2015) (0)
Distinct Phenotypic and Functional Immunological Alterations Characterize the Peripheral Blood Compartment of Patients with Diffuse Large B Cell Lymphoma (DLBCL). (2012) (0)
[Some aspects of polychemotherapy of acute leukemias]. (1971) (0)
Disease-specific prognostic factors for outcome of patients with poor-risk Myelodysplastic syndromes (MDS) and acute myeloid leukemia, treated with intensive antileukemic therapy (2003) (0)
Intensive chemotherapy versus autologous or allogeneic stemcell transplantation for the treatment of patients with poor risk MDS and secondary AML-A joint study of the Eortc, Ebmt, Hovon, Swiss, Scandinavian and Gimema leukemia groups: A biomed-2 EU-project. (1999) (0)
The Incidence of Central Nervous System Involvement in AML: A SAL-Tor Vergata Analysis (2011) (0)
PS968 GENETIC LANDSCAPE OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE) (2019) (0)
Flow-Cytometric Minimal Residual Disease Determination Is a Surrogate Prognosticator in Adult AML Patients Lacking Specific Molecular Signatures. (2007) (0)
Low cell concentration of cryopreserved autologous CD34+ peripheral blood progenitor cells does not impair hematopoietic recovery after transplantation. (2003) (0)
Clinical Relevance of Spontaneous Apoptosis Is Independent from Multidrug Resistance in Acute Myeloid Leukemia (AML). (2005) (0)
predicts outcome in acute myeloid leukemia (AML) The amount of spontaneous apoptosis detected by bax/bcl-2 ratio (2013) (0)
Statistical Validation of a Threshold To Discriminate Flow-Cytometry Minimal Residual Disease (MRD) Levels with Prognostic Significance in Acute Myeloid Leukemia (AML). (2006) (0)
High CD49d Protein Expression Predicts Short Overall Survival and Early Progression in Chronic Lymphocytic Leukemia Patients. (2007) (0)
Use of Plerixafor in Predicted and Proven Poor Mobilizer (according to GITMO criteria). Experience of Policlinico Universitario Tor Vergata (2012) (0)
Technical Advance An Allele-Specific RT-PCR Assay to Detect Type A Mutation of the Nucleophosmin-1 Gene in Acute Myeloid Leukemia (2008) (0)
Rituximab single agent in age-related Epstein–Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia (2014) (0)
The dose-response effect: a critical analysis. (1991) (0)
A Leukemia-Associated CD34/CD123/CD25/CD99-positive Immunophenotype Identifies FLT3 -mutated Clones in Acute Myeloid Leukemia (2015) (0)
acute myeloid leukemia mutations in (NPM) Immunohistochemistry predicts nucleophosmin (2011) (0)
Low Bax/Bcl-2 Ratio and NOTCH1 Mutations Represent Powerful and Synergistic Adverse Prognostic Factors within Trisomy 12 Chronic Lymphocytic Leukemia (CLL) (2016) (0)
Poster: AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3–Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML) (2022) (0)
Syndromes 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Valproic Acid at Therapeutic Plasma Levels May Increase (2009) (0)
Cytogenetic characteristics predict outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukaemia Groups (2002) (0)
Clinical Significance of Apoptosis in Chronic Lymphocytic Leukemia (CLL) (2014) (0)
The impact of cytogenetic features and clonality on the prognosis of patients with poor-risk MDS and secondary AML treated with intensive chemotherapy and stem cell transplantation: A joint study of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups (2000) (0)
Human acute myelogenous and lymphoid leukemias: pattern of expression of cellular oncogenes. (1987) (0)
[Red cell metabolism in premature infants (author's transl)]. (1975) (0)
Fatigue in long-term survivors of acute promyelocytic leukemia (APL) and its association with other symptoms and functional limitations. (2019) (0)
Mitoxantrone, Etoposide and Intermediate-dose Ara-C (MEC) for the Treatment of Acute Myelogenous Leukemia (AML) (1992) (0)
Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study (2016) (0)
Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study (2021) (0)
Breakthrough in supportive cancer care : introducing Pegfilgrastim (2004) (0)
Peptide-vaccine treatment associated with imatinib in patients with residual CML disease is able to induce both immunologic response and molecular remission. (2004) (0)
Rearrangement and Abnormal Expression of Human c-myc in Acute Lymphocytic Leukemia (1984) (0)
The Earliest Activation Marker CD69 Is An Independent and Strong Progression Indicator in B-Cell Chronic Lymphocytic Leukemia. (2009) (0)
Myelodysplastic Syndromes Myelodysplastic syndromes : recent advances (2001) (0)
[Clinical, erythrokinetic and metabolic aspects of congenital hemolytic non-spherocytic anemia due to erythrocytic glucose-6-phosphate dehydrogenase deficiency]. (1973) (0)
immune thrombocytopenic purpura: a systematic review Effects of eradication of Helicobacter pylori infection in patients with (2013) (0)
The impact of post-remission therapy on outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy with or without stem cell transplantation in a joint study (2004) (0)
myeloid leukemia Clinical relevance of P-glycoprotein expression in de novo acute (2011) (0)
Prof. Franco Mandelli Leukaemia Visionary. May 12, 1931– July 15, 2018 (2019) (0)
Sequential Pilot Studies of Intensive Postremission Chemotherapy for Acute Nonlymphocytic Leukemia (1987) (0)
Blood stem cell processing (1996) (0)
Abstract 4050: Association of long term NK cell culture and TIMP3 over-expression with NK cell reduced susceptibility to leukemia and epithelial cancer cell induced damage (2015) (0)
Clinical Monoclonal B Cell Lymphocytosis Is a Strong Favorable Prognosticator Independent From Biological and Clinical Parameters (2011) (0)
PS1011 MEASURABLE RESIDUAL DISEASE BY MULTIPARAMETRIC FLOW-CYTOMETRY IS A RELIABLE TOOL FOR RISK-STRATIFICATION OF FLT3-MUTATED AML PATIENTS (2019) (0)
Impact of Induction Regimen and of Allogeneic Hematopoietic Cell Transplantation on the Outcome in Younger Adults Patients with Acute Myeloid Leukemia with a Monosomal Karyotype: Results from the EORTC/Gimema AML-10 and AML-12 Trials (2016) (0)
Il farmacista e i network diagnostico-terapeutici in ematologia (2016) (0)
Remembering Professor Roberto Stasi (August 24th 1961 – January 28th 2014) (2014) (0)
Allogeneic transplantation for adult acute lymphoblastic leukemia: Intention to treat analysis of the EORTC ALL-4 phase III trial (2006) (0)
A Simple Clinical Prognostic Scoring System for Newly Diagnosed Cytogenetically Normal Acute Myeloid Leukemia: a Retrospective Analysis on 530 Patients (2010) (0)
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol (2022) (0)
Clinical Significance of 13q14 Number of Deleted Cells in Chronic Lymphocytic Leukemia (2012) (0)
Intensified Early Therapy for Childhood Acute Myeloid Leukemia: Pilot Studies of the AIEOP Cooperative Group (1997) (0)
New prognostic score based on clinical and biologic factors in patients < 56 years with poor-risk MDS and AML treated with intensive treatment (2005) (0)
vitro model for reactivation of human fetal globin genes Bromodeoxyuridine treatment of normal adult erythroid colonies: an in (2011) (0)
Clinical signiﬁcance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia (2006) (0)
Allogeneic but Not Autologous Stem Cell Transplant Attenuates the Negative Prognostic Impact Dictated By Pretransplant MRD Positivity (2014) (0)
A Distinctive Pattern of Different Gene Expression in Chronic Myelogenous Leukemia Patients (2008) (0)
Epidemiology and Characteristics of Pain in Blood-Related Disorders: A Longitudinal Study on Italian Adult Hospitalized Patients. (2006) (0)
Pyrrolo[1,2-B][1,2,5] benzodiazepines (PBTDs) Compounds Induce Apoptosis in Chronic Myeloid Leukaemia Cells from Patients at Onset, Imatinib and Second Generation TK Inhibitors (Dasatinib, Nilotinib) Resistant. (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Sergio Amadori?

Sergio Amadori is affiliated with the following schools:

Sergio Amadori's Academic­Influence.com Rankings

Sergio Amadori's Degrees

Similar Degrees You Can Earn

Why Is Sergio Amadori Influential?

Sergio Amadori's Published Works

Published Works

What Schools Are Affiliated With Sergio Amadori?

Sergio Amadori's AcademicInfluence.com Rankings